Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1362-1367

  Tuttle, Todd M ^a   Jarosek, Stephanie ^a   Habermann, Elizabeth B ^a   Arrington, Amanda ^a   Abraham, Anasooya ^a   Morris, Todd J ^a   Virnigl, Beth A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CARCINOMA IN SITU; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; TREATMENT INDICATION; TUMOR VOLUME; UNITED STATES; BREAST TUMOR; CANCER REGISTRY; COHORT ANALYSIS; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; STATISTICAL MODEL; UTILIZATION REVIEW;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MASTECTOMY; MIDDLE AGED; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 63049108940     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1681     Document Type: Article

References (15)

1. Baxter NN, Virnig BA, Durham SB, et al: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96:443-448, 2004
2. Fisher ER, Dignam J, Tan-Chiu E, et al: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma. Cancer 86:429-438, 1999
3. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A populationbased study. Int J Radiat Oncol Biol Phys 56:1038-1045, 2003
4. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
5. Fisher ER, Land SR, Saad RS, et al: Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol 128:86-91, 2007
6. Tuttle TM, Habermann E, Grund E, et al: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol 25:5203-5209, 2007
7. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER): About SEER. Http://www.seer.cancer.gov/about/
8. Goldflam K, Hunt KK, Gershenwald JE, et al: Contralateral prophylactic mastectomy: Predictors of significant histologic findings. Cancer 101:1977-1986, 2004
9. Peralta EA, Ellenhorn JD, Wagman LD, et al: Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439-445, 2000
10. McDonnell SK, Schaid DJ, Myers JL, et al: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938-3943, 2001
11. Herrinton LJ, Barlow WE, Yu O, et al: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol 23:4275-4286, 2005
12. van Sprundel TC, Schmidt MK, Rookus MA, et al: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287-292, 2005
13. Houghton J, George WD, Cuzick J, et al: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet 362:95-102, 2003
14. Katipamula R, Hoskin TL, Boughey JC, et al: Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and preoperative MRI. J Clin Oncol 26:9s, 2008 (suppl; abstr 509)
15. Montgomery LL, Tran KN, Heelan MC, et al: Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6:546-552, 1999